PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28665978-9 2017 Our results demonstrated testosterone not only suppressed the invasion and colonization of UPEC, but also inhibited the expression of pro-inflammatory IL-1beta, IL-6 and IL-8 cytokines expression induced by UPEC in a dose-dependent manner. Testosterone 25-37 interleukin 6 Homo sapiens 161-165 26849353-7 2016 Results from group analysis suggested that high IL-6 levels in PCOS were significantly associated with Homeostasis Model Assessment of Insulin Resistance (HOMA2-IR) ratio and total testosterone ratio (T ratio), and was found in both lean and obese women with PCOS. Testosterone 181-193 interleukin 6 Homo sapiens 48-52 28019133-8 2017 A relationship was detected between H score, FSH, LH, total testosterone, HDL-C and TG levels and CG + GG genotypes of IL-6. Testosterone 60-72 interleukin 6 Homo sapiens 119-123 27666890-3 2016 Testosterone 10 mumol/L was added into indirect co-culture for 24 h. ELISA was used to testing IL-6, MCP-1 concentrations in supernatant. Testosterone 0-12 interleukin 6 Homo sapiens 95-99 27666890-6 2016 Results: Testosterone enhanced inflammatory cytokines (IL-6, MCP-1) production in indirect co-culture of 3T3-L1 adipocytes and RAW264.7 macrophages, promoted the activation of ERK1/2 and nuclear factor kappa B p65, and inhibited glucose uptake in adipocytes. Testosterone 9-21 interleukin 6 Homo sapiens 55-59 24956549-8 2014 The MNC-derived TNF-alpha and IL-6 responses from MNCs were negatively correlated with insulin sensitivity (P < .03) and positively correlated with testosterone (P < .03) and androstenedione (P < .006) for the combined groups. Testosterone 151-163 interleukin 6 Homo sapiens 30-34 25710413-9 2015 Elevated TT levels at 6 hours were associated with elevated interleukin 6 levels and cytokine/chemokine measurements (18 of 24 measured). Testosterone 9-11 interleukin 6 Homo sapiens 60-73 25738264-0 2015 Testosterone enhances lipopolysaccharide-induced interleukin-6 and macrophage chemotactic protein-1 expression by activating the extracellular signal-regulated kinase 1/2/nuclear factor-kappaB signalling pathways in 3T3-L1 adipocytes. Testosterone 0-12 interleukin 6 Homo sapiens 49-62 25738264-7 2015 Testosterone induces IL-6 and MCP-1, and enhances LPS-induction of IL-6 and MCP-1. Testosterone 0-12 interleukin 6 Homo sapiens 21-25 25738264-7 2015 Testosterone induces IL-6 and MCP-1, and enhances LPS-induction of IL-6 and MCP-1. Testosterone 0-12 interleukin 6 Homo sapiens 67-71 25738264-10 2015 The effect of testosterone on the expression of IL-6 and MCP-1 is inhibited by PD98059 , an ERK1/2 inhibitor, and PDTC, an NF-kappaB inhibitor. Testosterone 14-26 interleukin 6 Homo sapiens 48-52 25738264-11 2015 The results indicate that testosterone enhances LPS-induced IL-6 and MCP-1 expression by activating the ERK1/2/NF-kappaB signalling pathways in 3T3-L1 adipocytes. Testosterone 26-38 interleukin 6 Homo sapiens 60-64 24576416-10 2014 The absolute change in plasma IL-6 correlated positively with testosterone. Testosterone 62-74 interleukin 6 Homo sapiens 30-34 22752961-8 2012 The testosterone reduction was related to increases in weight and IL-6. Testosterone 4-16 interleukin 6 Homo sapiens 66-70 23979817-6 2014 Serum total testosterone was inversely correlated with age (r = -0.32, p < 0.05), CRP (r = -0.31, p < 0.05), and IL-6 (r = -0.24, p < 0.05). Testosterone 12-24 interleukin 6 Homo sapiens 119-123 23280522-7 2013 Testosterone also decreased TNF-alpha and IL6 production by pSMCs after LPS as quantified by ELISA. Testosterone 0-12 interleukin 6 Homo sapiens 42-45 22213519-4 2012 RESULTS: Before ADT, serum interleukin-6 levels were inversely correlated with serum total-testosterone (rs = -0.305, P = 0.009) and dihydrotestosterone (rs = -0.380, P = 0.006) concentrations, but not correlated with adrenal androgen or estradiol levels. Testosterone 91-103 interleukin 6 Homo sapiens 27-40 22213519-7 2012 After ADT, in contrast to the pretreatment relationship, interleukin-6 levels were positively correlated with total-testosterone concentrations (rs = 0.343, P = 0.003), and were positively correlated also with levels of androstenedione (rs = 0.351, P = 0.002) and estoradiol (rs = 0.335, P = 0.004). Testosterone 116-128 interleukin 6 Homo sapiens 57-70 22213519-9 2012 CONCLUSIONS: Posttreatment interleukin-6 levels had a strong positive correlation with total-testosterone, androstenedione, and estradiol levels, suggesting that a regulation loop may emerge between these sex steroids and interleukin-6 during ADT. Testosterone 93-105 interleukin 6 Homo sapiens 27-40 22031502-10 2011 Only interleukin-6 appeared to be exclusively dependent on long-term testosterone application. Testosterone 69-81 interleukin 6 Homo sapiens 5-18 21239514-6 2011 In addition, testosterone was positively associated with CRP (P = 0.006), IL-6 (P = 0.001), and TNF-alpha (P = 0.0002). Testosterone 13-25 interleukin 6 Homo sapiens 74-78 19638459-13 2009 Treatment of IL-6 increased testosterone level in LNCaP cells. Testosterone 28-40 interleukin 6 Homo sapiens 13-17 23008706-10 2011 The free testosterone had significant negative correlation with fibrinogen, PAI-1, hsCRP and IL-6 in both groups of patients. Testosterone 9-21 interleukin 6 Homo sapiens 93-97 20624775-7 2011 Testosterone was strongly and inversely correlated to inflammatory markers (CRP, IL-6 and fibrinogen), even after correction for age and sex hormone-binding globulin. Testosterone 0-12 interleukin 6 Homo sapiens 81-100 19144759-4 2009 Independent of age, serum creatinine, and sexual hormone binding globulin (SHBG), testosterone levels inversely and strongly associated with the inflammatory markers IL-6 and CRP. Testosterone 82-94 interleukin 6 Homo sapiens 166-170 15240608-1 2004 Testosterone has immune-modulating properties, and current in vitro evidence suggests that testosterone may suppress the expression of the proinflammatory cytokines TNFalpha, IL-1beta, and IL-6 and potentiate the expression of the antiinflammatory cytokine IL-10. Testosterone 91-103 interleukin 6 Homo sapiens 189-193 16731790-4 2006 Our results show for the first time that testosterone-replacement therapy is associated with a reduction or complete abrogation of spontaneous ex vivo production of IL-1beta, IL-6 and TNFalpha by APCs. Testosterone 41-53 interleukin 6 Homo sapiens 175-179 16040142-15 2006 Statistical analysis revealed that testosterone treatment prior to stent implantation attenuated IL-6 and hs-CRP levels significantly (P=0.042 and P=0.043; respectively). Testosterone 35-47 interleukin 6 Homo sapiens 97-101 16040142-16 2006 CONCLUSIONS: The present study shows that 3 weeks testosterone treatment prior to intracoronary stenting results in a significant suppression in hs-CRP and IL-6 levels after the stent implantation. Testosterone 50-62 interleukin 6 Homo sapiens 156-160 16130198-14 2005 Correlation analysis showed that FT (free testosterone) had negative correlation with CRP, IL-6 and sICAM-1. Testosterone 42-54 interleukin 6 Homo sapiens 91-95 19050054-6 2009 RESULTS: In age-adjusted analysis, log (E2) was positively associated with log (IL-6) (r = 0.19; P = 0.047), and the relationship was statistically significant (P = 0.032) after adjustments for age, BMI, smoking, physical activity, chronic disease, and serum testosterone levels. Testosterone 259-271 interleukin 6 Homo sapiens 80-84 17911176-8 2008 The low testosterone-mortality association was also independent of the metabolic syndrome, diabetes, and prevalent cardiovascular disease but was attenuated by adjustment for IL-6 and C-reactive protein. Testosterone 8-20 interleukin 6 Homo sapiens 175-179 17468196-10 2007 There was a significant inverse correlation between baseline IL-6 and total testosterone (r=-0.68; P=0.002) and bioavailable testosterone levels (r=-0.73; P=0.007). Testosterone 76-88 interleukin 6 Homo sapiens 61-65 16914597-7 2006 Serum IL-6 levels correlated significantly (P < 0.05) with testosterone and estradiol levels (r=-0.37 and -0.42 respectively), whereas estradiol, but not testosterone, correlated with leptin/receptor ratio (r=0.59; P < 0.001). Testosterone 62-74 interleukin 6 Homo sapiens 6-10 16930264-5 2006 In addition, testosterone levels were inversely correlated with IL-6 and TNF-alpha. Testosterone 13-25 interleukin 6 Homo sapiens 64-68 16688773-16 2006 The authors postulated that high IL-6 or ghrelin levels inhibit testosterone synthesis, although a secondary effect at the hypothalamic-pituitary levels cannot be excluded. Testosterone 64-76 interleukin 6 Homo sapiens 33-37 16204370-10 2005 During the pharmacological trial, the testosterone/progestin group exhibited a marked increase of IL-6 concentrations (P < 0.001), whereas these decreased in the testosterone/placebo group (P = 0.03). Testosterone 38-50 interleukin 6 Homo sapiens 98-102 15313415-3 2004 After menopause or andropause, loss of the normally inhibiting sex steroids (estrogen, testosterone) results in elevated IL6 levels that are further progressively increasing with age. Testosterone 87-99 interleukin 6 Homo sapiens 121-124 12030972-0 2002 Testosterone stimulates proliferation and inhibits interleukin-6 production of normal and hereditary gingival fibromatosis fibroblasts. Testosterone 0-12 interleukin 6 Homo sapiens 51-64 12210475-3 2002 METHODS: By using enzyme-linked immunosorbent assay analyses, promatrilysin was measured in LNCaP cells stimulated with IL-1 beta or IL-6 LNCaP-treated cells pretreated with testosterone. Testosterone 174-186 interleukin 6 Homo sapiens 133-137 12210475-4 2002 In addition, promatrilysin message was measured by using Northern analyses after IL-6-treated cells pretreated with testosterone. Testosterone 116-128 interleukin 6 Homo sapiens 81-85 12210475-6 2002 Furthermore, testosterone completely abrogated NF kappa B transactivation activity and induction of IL-6 protein expression and mRNA. Testosterone 13-25 interleukin 6 Homo sapiens 100-104 12210475-9 2002 CONCLUSION: From these data, we conclude that testosterone blocks IL-1 beta-induced promatrilysin expression by inhibition of NF kappa B transactivation activity, which in turn, blocks IL-6 expression. Testosterone 46-58 interleukin 6 Homo sapiens 185-189 12030972-11 2002 These results show that testosterone coordinates the proliferation and production of IL-6 of normal and HGF fibroblasts. Testosterone 24-36 interleukin 6 Homo sapiens 85-89 11959895-8 2002 RESULTS: Levels of IL-6 mRNA and protein increased in all cells treated with follicle-stimulating hormone (FSH), luteinizing hormone (LH), 17beta-estradiol, or estrone but increased only in OVCA cells treated with testosterone and 5alpha-dihydrotestosterone. Testosterone 214-226 interleukin 6 Homo sapiens 19-23 10397515-10 1999 CONCLUSIONS: We concluded that elevated levels of androgens, specifically testosterone and dihydrotestosterone, could affect the stromal cell response to an inflammatory challenge by downregulation of IL-6 production. Testosterone 74-86 interleukin 6 Homo sapiens 201-205 10729217-7 2000 In contrast, beta-estradiol and testosterone increased LPS-induced IL-6 secretion in six of seven time points during the MC (significant for testosterone, p = .005). Testosterone 32-44 interleukin 6 Homo sapiens 67-71 10729217-7 2000 In contrast, beta-estradiol and testosterone increased LPS-induced IL-6 secretion in six of seven time points during the MC (significant for testosterone, p = .005). Testosterone 141-153 interleukin 6 Homo sapiens 67-71 10774463-2 2000 Among several factors that down-regulate IL-6 gene expression are estrogen and testosterone. Testosterone 79-91 interleukin 6 Homo sapiens 41-45 10574620-9 1999 The three higher IL-6 doses, however, caused significant decreases in testosterone levels by 24 h, which persisted at 48 h and returned to baseline by 7 days. Testosterone 70-82 interleukin 6 Homo sapiens 17-21 10574620-11 1999 There also appeared to be small but not significant increases in LH levels after the three higher IL-6 doses, which were not acute and seemed to follow temporally the testosterone decreases. Testosterone 167-179 interleukin 6 Homo sapiens 98-102 10574620-13 1999 In conclusion, subcutaneous IL-6 administration, which caused acute elevations in circulating IL-6 levels of a similar magnitude to those observed in severe inflammatory and noninflammatory stress, induced prolonged suppression in testosterone levels in healthy men without apparent changes in gonadotropin levels. Testosterone 231-243 interleukin 6 Homo sapiens 28-32 10574620-13 1999 In conclusion, subcutaneous IL-6 administration, which caused acute elevations in circulating IL-6 levels of a similar magnitude to those observed in severe inflammatory and noninflammatory stress, induced prolonged suppression in testosterone levels in healthy men without apparent changes in gonadotropin levels. Testosterone 231-243 interleukin 6 Homo sapiens 94-98 10616034-8 1999 Testosterone likewise can inhibit IL-6 induction in androgen-responsive cells, which may include brain glia and astrocytes. Testosterone 0-12 interleukin 6 Homo sapiens 34-38 10457265-4 1999 Treatment with 5alpha-dihydrotestosterone (DHT) dose-dependently inhibited constitutive and TNF-alpha/IL-1beta-stimulated IL-6 mRNA steady-state levels in hFOB/AR-6 cells by 70-80% at 10-7 M. In addition, testosterone also suppressed TNF-alpha/IL-1beta-stimulated IL-6 mRNA levels by 57%, while the adrenal androgen dehydroepiandrosterone had no effect. Testosterone 29-41 interleukin 6 Homo sapiens 122-126 10457265-4 1999 Treatment with 5alpha-dihydrotestosterone (DHT) dose-dependently inhibited constitutive and TNF-alpha/IL-1beta-stimulated IL-6 mRNA steady-state levels in hFOB/AR-6 cells by 70-80% at 10-7 M. In addition, testosterone also suppressed TNF-alpha/IL-1beta-stimulated IL-6 mRNA levels by 57%, while the adrenal androgen dehydroepiandrosterone had no effect. Testosterone 29-41 interleukin 6 Homo sapiens 264-268 10457265-6 1999 Consistent with the Northern analyses, treatment with 5alpha-DHT, testosterone, and hydroxyflutamide also inhibited IL-6 protein production by 79%, 62%, and 71%, respectively (p < 0.001), while these agents had no effect on IL-6 soluble receptor levels. Testosterone 66-78 interleukin 6 Homo sapiens 116-120 10457265-6 1999 Consistent with the Northern analyses, treatment with 5alpha-DHT, testosterone, and hydroxyflutamide also inhibited IL-6 protein production by 79%, 62%, and 71%, respectively (p < 0.001), while these agents had no effect on IL-6 soluble receptor levels. Testosterone 66-78 interleukin 6 Homo sapiens 227-231 9324026-6 1997 Interleukin-6 (IL-6) partially restored the testosterone-induced decrease in antibody levels in PBMC. Testosterone 44-56 interleukin 6 Homo sapiens 0-13 9699868-11 1998 Moreover, IL-4 and IL-6 exerted the same regulatory effects on 17beta-HSD activities when testosterone and 4-dione were used as substrates, thus strongly suggesting the expression of the type 2 17beta-HSD ZR-75-1 cells. Testosterone 90-102 interleukin 6 Homo sapiens 19-23 9324026-6 1997 Interleukin-6 (IL-6) partially restored the testosterone-induced decrease in antibody levels in PBMC. Testosterone 44-56 interleukin 6 Homo sapiens 15-19 9324026-7 1997 Testosterone reduced IL-6 production in monocytes. Testosterone 0-12 interleukin 6 Homo sapiens 21-25 9324026-8 1997 CONCLUSION: These results suggest that testosterone may directly suppress anti-DNA antibody production in PBMC from SLE patients by inhibiting B cell hyperactivity and, indirectly, by down-regulating IL-6 production in monocytes. Testosterone 39-51 interleukin 6 Homo sapiens 200-204 2104896-9 1990 Analysis of hormonal influences on chondrocyte IL-6 production showed that testosterone and estradiol synergized with IL-1 in the induction of IL-6. Testosterone 75-87 interleukin 6 Homo sapiens 47-51 8918592-7 1996 Exogenous IL-6 partially restored the impaired immunoglobulin production of testosterone-treated PBMC; IgG production in testosterone culture was increased by IL-6 from 35.6% to 66.5% of control and that of IgM was also increased from 38.9% to 71.2%, respectively. Testosterone 76-88 interleukin 6 Homo sapiens 10-14 8918592-7 1996 Exogenous IL-6 partially restored the impaired immunoglobulin production of testosterone-treated PBMC; IgG production in testosterone culture was increased by IL-6 from 35.6% to 66.5% of control and that of IgM was also increased from 38.9% to 71.2%, respectively. Testosterone 76-88 interleukin 6 Homo sapiens 159-163 8918592-7 1996 Exogenous IL-6 partially restored the impaired immunoglobulin production of testosterone-treated PBMC; IgG production in testosterone culture was increased by IL-6 from 35.6% to 66.5% of control and that of IgM was also increased from 38.9% to 71.2%, respectively. Testosterone 121-133 interleukin 6 Homo sapiens 10-14 8918592-7 1996 Exogenous IL-6 partially restored the impaired immunoglobulin production of testosterone-treated PBMC; IgG production in testosterone culture was increased by IL-6 from 35.6% to 66.5% of control and that of IgM was also increased from 38.9% to 71.2%, respectively. Testosterone 121-133 interleukin 6 Homo sapiens 159-163 8918592-8 1996 Testosterone treatment reduced IL-6 production of monocytes by 78.4% compared with control, but neither affected that of T cells or B cells. Testosterone 0-12 interleukin 6 Homo sapiens 31-35 8918592-9 1996 These results suggest that testosterone may suppress immunoglobulin production of human PBMC directly by inhibiting B cell activity and indirectly by reducing IL-6 production of monocytes. Testosterone 27-39 interleukin 6 Homo sapiens 159-163 7769130-5 1995 In addition, testosterone, dihydrotestosterone, and adrenal androgens inhibited the expression of a chloramphenicol acetyl transferase reporter plasmid driven by the human IL-6 promoter in HeLa cells cotransfected with an androgen receptor expression plasmid; however, these steroids were ineffective when the cells were cotransfected with an estrogen receptor expression plasmid. Testosterone 13-25 interleukin 6 Homo sapiens 172-176 2104896-9 1990 Analysis of hormonal influences on chondrocyte IL-6 production showed that testosterone and estradiol synergized with IL-1 in the induction of IL-6. Testosterone 75-87 interleukin 6 Homo sapiens 143-147 34935398-9 2022 Conclusions During systemic inflammatory activation, interleukin-6 elevation is associated with reduced testosterone levels in males, possibly deriving from an enhanced androgen-to-estrogen conversion. Testosterone 104-116 interleukin 6 Homo sapiens 53-66 34661247-7 2021 Spearman"s correlation analysis revealed that total testosterone levels were significantly and inversely correlated with NLR, high-sensitivity C-reactive protein (hsCRP), interleukin-6, D-dimer and PCT. Testosterone 52-64 interleukin 6 Homo sapiens 171-184 34453520-6 2021 Poly(I:C) dramatically induced the expression of the pro-inflammatory cytokines TNF-alpha and IL-6 in SC and LC through Toll-like receptor 3 and IFN-beta promoter stimulator 1 signaling pathways, impairing the integrity of the blood-testis barrier and testosterone synthesis. Testosterone 252-264 interleukin 6 Homo sapiens 94-98 34409772-9 2022 Baseline Charlson Comorbidity Index score (OR 0.36; p = 0.03 (0.14, 0.89)) was independently associated with total testosterone levels at 7-month follow-up, after adjusting for age, BMI, and IL-6 at hospital admittance. Testosterone 115-127 interleukin 6 Homo sapiens 191-195 33378113-11 2021 CONCLUSIONS: Results of this preliminary study suggest that increases in circulating IL-6, perhaps due to testosterone inhibition, may play a role in fatigue secondary to receipt of ADT. Testosterone 106-118 interleukin 6 Homo sapiens 85-89 33080435-5 2020 Impaired spermatogenesis via COVID-19 decreases the level of testosterone by disturbing cytokines such as TNF-alpha, IL-4, IL-6, and IL-12 and further, attenuates the sperm count. Testosterone 61-73 interleukin 6 Homo sapiens 123-127 33849511-13 2021 Salivary testosterone was positively correlated with TNF-alpha in the control group (rs = 0.41, p = 0.0321), while in the study group, total testosterone (TT) was positively correlated with IL-6 (rs = 0.37, p = 0.0400) and free androgen index (FAI) with TNF-alpha (rs = 0.36, p = 0.0491). Testosterone 141-153 interleukin 6 Homo sapiens 190-194 29925283-6 2019 The suppression of inflammation by testosterone were observed in patients with coronary artery disease, prostate cancer and diabetes mellitus through the increase in anti-inflammatory cytokines (IL-10) and the decrease in pro-inflammatory cytokines (IL-1beta, IL-6, and TNF-alpha). Testosterone 35-47 interleukin 6 Homo sapiens 260-264 31293514-8 2019 There was a significant positive correlation between ASP levels with CRP (p < 0.01), testosterone (p < 0.01) and HOMA-IR (p < 0.01); IL-6 levels with CRP (p <0.01) and testosterone (p < 0.01) and MCP-1 with CRP (p < 0.01); testosterone (p < 0.01) and HOMA-IR (p < 0.02). Testosterone 180-192 interleukin 6 Homo sapiens 142-146 31475727-5 2019 The nadir in serum testosterone preceded the post-prandial increase in serum IL-6/IL-17 by several hours, suggesting that inflammation was unlikely the cause. Testosterone 19-31 interleukin 6 Homo sapiens 77-81 29183872-7 2018 Multivariate analysis revealed a significant, negative correlation between serum IL-6 and free testosterone. Testosterone 95-107 interleukin 6 Homo sapiens 81-85 31293514-8 2019 There was a significant positive correlation between ASP levels with CRP (p < 0.01), testosterone (p < 0.01) and HOMA-IR (p < 0.01); IL-6 levels with CRP (p <0.01) and testosterone (p < 0.01) and MCP-1 with CRP (p < 0.01); testosterone (p < 0.01) and HOMA-IR (p < 0.02). Testosterone 180-192 interleukin 6 Homo sapiens 142-146 31938083-0 2018 Synergistic effect of estradiol and testosterone protects against IL-6-inducedcardiomyocyte apoptosismediated by TGF-beta1. Testosterone 36-48 interleukin 6 Homo sapiens 66-70